Handling of allergen immunotherapy in the COVID‐19 pandemic: An ARIA‐EAACI statement
- Klimek, Ludger
- Jutel, Marek
- Akdis, Cezmi
- Bousquet, Jean
- Akdis, Mübeccel
- Bachert, Claus
- Agache, Ioana
- Ansotegui, Ignacio
- Bedbrook, Anna
- Bosnic-Anticevich, Sinthia
- Canonica, Giorgio
- Chivato, Tomas
- Cruz, Alvaro
- Czarlewski, Wienia
- del Giacco, Stefano
- Du, Hui
- Fonseca, Joao
- Gao, Yadong
- Haahtela, Tari
- Hoffmann-Sommergruber, Karin
- Ivancevich, Juan-Carlos
- Khaltaev, Nikolai
- Knol, Edward
- Kuna, Piotr
- Larenas-Linnemann, Desiree
- Melén, Erik
- Mullol, Joaquim
- Naclerio, Robert
- Ohta, Ken
- Okamoto, Yoshitaka
- O'Mahony, Liam
- Onorato, Gabrielle
- Papadopoulos, Nikos
- Pawankar, Ruby
- Pfaar, Oliver
- Samolinski, Boleslaw
- Schwarze, Jurgen
- Toppila-Salmi, Sanna
- Shamji, Mohamed
- Teresa Ventura, Maria
- Valiulis, Arunas
- Yorgancioglu, Arzu
- Matricardi, Paolo
- Zuberbier, Torsten
DOIAbstract
International audienceThe current COVID‐19 pandemic influences many areas of social life, medical treatments and the way allergy is performed. Allergen‐specific immunotherapy (AIT) is one of the most important treatment options for IgE‐mediated allergies and is based on immunological effects on the diseased patient
Add to ORKG